Source: Annual Congress 2004 - Epidemiology: miscellaneous including cancer
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. M. Gagnon, A. H. Briggs, A. R. Levy, S. Spencer, G. Bale, M. D. Spencer, P. S. Burge (Vancouver, Canada; Oxford, London, Birmingham, United Kingdom). Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease. Eur Respir J 2004; 24: Suppl. 48, 3686

Member's Comments

No comment yet.

Related content which might interest you: One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Source: Eur Respir J 2004; 23: 241-249 Year: 2004 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003 Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Inhaled budesonide in the management of chronic obstructive pulmonary diseases Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Source: Eur Respir J 2003; 21: 68-73 Year: 2003 Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 546s Year: 2007 Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Source: Eur Respir J 2013; 41: 12-17 Year: 2013 Efficacy of tiotropium bromide in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002